Did thiazolidinediones affect the visual or retinal thickness outcomes of ranibizumab (Lucentis) in diabetic macular oedema studies?

In clinical studies treating visual impairment due to diabetic macular oedema, concomitant thiazolidinediones did not affect visual acuity or central retinal subfield thickness outcomes in patients receiving ranibizumab (Lucentis).